베바시주맙이 섬유주세포의 생존과 일산화질소의 생성에 미치는 영향 = Effect of Bevacizumab on Survival and Production of Nitric Oxide in Trabecular Meshwork Cells

다국어 초록 (Multilingual Abstract)

Purpose: To investigate the effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF),
on the survival and production of nitric oxide (NO) in human trabecular meshwork cells (HTMC).
Methods: Primarily cultured HTMC were exposed to 0, 0.25, 1.0, and 2.5 mg/ml bevacizumab for 24 hours. Cellular survival
and production of NO were assessed by MTT assay and Griess assay, respectively.
Results: Bevacizumab did not affect the cellular survival at low concentrations but decreased cellular survival significantly at
high concentrations (>1.0 mg/ml) accompanied with increased NO production.
Conclusions: High concentrations of bevacizumab may be toxic to HTMC

국문 초록 (Abstract)

목적: 신생혈관의 치료에 사용하는 혈관내피성장인자에 대한 단클론 항체인 bevacizumab이 인체의 섬유주세포의 생존과 일산화질소
(NO)의 생성에 미치는 영향에 대해 알아보고자 하였다.
대상과 방법: 인체의 섬유주세포를 일차배양하여 0, 0.25, 0.5, 1.0, 2.5 mg/ml의 bevacizumab에 24시간 노출시킨 후 세포의 생존과
NO의 생성을 MTT assay와 Griess assay로 각각 조사하였다.
결과: Bevacizumab는 저농도에서는 NO의 생성저하와 함께 세포의 생존에 유의한 영향을 미치지 않았으나 0.1 mg/ml의 고농도에서는
세포의 생존을 유의하게 감소시켰다.
결론: 고농도의 bevacizumab에 섬유주세포가 직접 노출될 경우 섬유주세포에 심각한 손상을 유발할 수 있으므로 주의를 요한다.

참고문헌 (Reference)

1 Bouloumie A, "Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells" 41 : 773-780, 1999

2 Avery RL, "Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment" 26 : 352-354, 2006

3 Davidorf FH, "Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection" 26 : 354-356, 2006

4 Mosmann T, "Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays" 65 : 55-63, 1983

5 Bakri SJ, "Pharmacokinetics of intravitreal bevacizumab (Avastin)" 114 : 855-859, 2007

6 Rosenfeld PJ, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration" 36 : 331-335, 2005

7 Schuman JS, "Nitrovasodilator effects on intraocular pressure and ocular facility in monkeys" 58 : 99-105, 1994

8 Moncada S, "Nitric oxide: physiology, pathophysiology, and pharmacology" 43 : 109-142, 1991

9 Bredt DS, "Nitric oxide: a physiologic messenger molecule" 63 : 175-195, 1994

10 Geyer O, "Nitric oxide synthase activity in tissues of the bovine eyes" 235 : 786-793, 1997

11 Dulak J, "Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells" 20 : 659-666, 2000

12 Brüne B, "Nitric oxide and its role in apoptosis" 351 : 261-272, 1998

13 Roberts DD, "Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis" 13 : 795-798, 2007

14 Meyer P, "Localization of nitric oxide synthase isoforms in porcine ocular tissues" 18 : 375-380, 1999

15 Spaide RF, "Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage" 26 : 275-278, 2006

16 Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration" 113 : 363-372, 2006

17 Nathanson JA, "Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway" 36 : 1765-1773, 1995

18 Alvarado JA, "Human trabecular cells. II. Growth pattern and ultrastructural characteristics" 23 : 464-478, 1982

19 Polansky JR, "Human trabecular cells. I. Establishment in tissue culture and growth characteristics" 18 : 1043-1049, 1979

20 Wana RF, "Effect of the topical application of nitroglycerin on intraocular pressure in normal and glaucomatous monkeys" 60 : 337-339, 1995

21 Iriyama A, "Effect of anti-VEGF on retinal gangion cells in rats" 91 : 1230-1233, 2007

22 Wiederholt M, "Dirtect involvement of trabecular meshwork in the regulation of aqueous humor outflow" 9 : 46-49, 1998

23 Spitzer MS, "Comparative antiproliferative and cytotoxic profile of bevacizuman (Avastin), pegaptanib (macugen) and ranibizumab (Lucentis) on different ocular cells" 245 : 1837-1842, 2007

24 Kernt M, "Bevacizumab is not toxic to human anterior- and posterior-segment" 104 : 965-971, 2007

25 Matsuo T, "Basic nitric oxide production is enhanced by hydraulic pressure in cultured human trabecular cells" 84 : 631-635, 2000

26 Green LC, "Analysis of nitrate, nitrite and [15N]nitrate in biologic fluids" 126 : 131-138, 1982

27 Nathanson JA, "Alteration of ocular nitric oxide synthase in human glaucoma" 36 : 1774-1784, 1995